Symbols / DYN Stock $17.29 -5.42% Dyne Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
DYN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. John G. Cox M.B.A.
Exch · Country NMS · United States
Market Cap 2.86B
Enterprise Value 2.05B
Income -451.71M
Sales —
FCF (ttm) -292.28M
Book/sh 5.89
Cash/sh 5.88
Employees 263
Insider 10d —
IPO Sep 17, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -5.75
PEG —
P/S —
P/B 2.93
P/C —
EV/EBITDA -4.38
EV/Sales —
Quick Ratio 18.97
Current Ratio 19.92
Debt/Eq 19.50
LT Debt/Eq —
EPS (ttm) -3.15
EPS next Y -3.01
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-07-27
Earnings (prior) 2026-05-11
ROA -32.70%
ROE -58.89%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 165.31M
Shs Float 164.82M
Insider Own 0.28%
Instit Own 115.17%
Short Float 16.66%
Short Ratio 11.73
Short Interest 20.73M
52W High 25.00
vs 52W High -30.84%
52W Low 8.06
vs 52W Low 114.52%
Beta 1.08
Impl. Vol. 1.61%
Rel Volume 0.59
Avg Volume 2.02M
Volume 1.20M
Target (mean) $38.25
Tgt Median $39.50
Tgt Low $16.00
Tgt High $50.00
# Analysts 16
Recom Strong_buy
Prev Close $18.28
Price $17.29
Change -5.42%
About

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$38.25
Mean price target
2. Current target
$17.29
Latest analyst target
3. DCF / Fair value
$-31.82
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$17.29
Low
$16.00
High
$50.00
Mean
$38.25

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-15 main Evercore ISI Group Outperform → Outperform $33
2026-05-13 main Bernstein Market Perform → Market Perform $24
2026-03-09 main Chardan Capital Buy → Buy $38
2026-03-03 main Morgan Stanley Overweight → Overweight $47
2026-03-03 main Chardan Capital Buy → Buy $38
2026-03-03 main HC Wainwright & Co. Buy → Buy $50
2026-01-20 main JP Morgan Neutral → Neutral $16
2025-12-15 main Evercore ISI Group Outperform → Outperform $36
2025-12-11 main Stifel Buy → Buy $39
2025-12-10 up Oppenheimer Perform → Outperform $40
2025-12-09 main Morgan Stanley Overweight → Overweight $50
2025-12-09 main Chardan Capital Buy → Buy $38
2025-12-08 main HC Wainwright & Co. Buy → Buy $60
2025-11-14 main JP Morgan Neutral → Neutral $17
2025-11-12 main Oppenheimer Perform → Perform $11
2025-11-06 main HC Wainwright & Co. Buy → Buy $46
2025-11-06 main RBC Capital Outperform → Outperform $30
2025-10-10 down Oppenheimer Outperform → Perform $13
2025-08-25 up Raymond James Outperform → Strong Buy $35
2025-08-06 main Oppenheimer Outperform → Outperform $13
News
RSS: Latest DYN news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-13 LUCERA ERICK J. Chief Financial Officer — 1,448 $18.36 $26,585
2026-05-13 KERR DOUGLAS Officer — 1,564 $18.36 $28,715
2026-05-13 COX JOHN Chief Executive Officer — 3,311 $18.36 $60,790
2026-05-13 FRIEDL-NADERER JOHANNA Officer — 228 $18.36 $4,186
2026-05-06 RHODES JASON P Director — 106,723 $18.00 $1,936,341
2026-04-28 RHODES JASON P Director — 227,337 $18.38 $4,178,516
2026-04-27 RHODES JASON P Director — 384,549 $18.15 $7,101,120
2026-04-24 LUBNER DAVID CHARLES Director — 53,625 $0.00 $0
2026-04-22 RHODES JASON P Director — 834,302 $19.51 $16,477,388
2026-04-22 KERSTEN DIRK Director — 10,952 $20.00 $219,170
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
468.18
+36.15%
343.89
+42.01%
242.16
+41.65%
170.96
Research And Development
398.33
+41.55%
281.41
+33.52%
210.76
+47.63%
142.76
Selling General And Administration
69.85
+11.80%
62.48
+98.98%
31.40
+11.34%
28.20
General And Administrative Expense
69.85
+11.80%
62.48
+98.98%
31.40
+11.34%
28.20
Salaries And Wages
38.52
-2.89%
39.67
+120.16%
18.02
+22.16%
14.75
Other Gand A
31.33
+37.34%
22.81
-27.35%
31.40
+11.34%
28.20
Total Expenses
468.18
+36.15%
343.89
+42.01%
242.16
+41.65%
170.96
Operating Income
-468.18
-36.15%
-343.89
-42.01%
-242.16
-41.65%
-170.96
Total Operating Income As Reported
-468.18
-36.15%
-343.89
-42.01%
-242.16
-41.65%
-170.96
EBITDA
-437.97
-38.71%
-315.75
-34.78%
-234.26
-38.39%
-169.28
Normalized EBITDA
-437.97
-38.71%
-315.75
-34.78%
-234.26
-38.39%
-169.28
Reconciled Depreciation
2.05
+22.47%
1.67
+0.00%
1.67
-0.59%
1.68
EBIT
-440.02
-38.63%
-317.42
-34.54%
-235.94
-38.01%
-170.96
Net Income
-446.21
-40.58%
-317.42
-34.54%
-235.94
-40.36%
-168.10
Pretax Income
-446.21
-40.58%
-317.42
-34.54%
-235.94
-40.36%
-168.10
Net Non Operating Interest Income Expense
23.67
-12.09%
26.92
+252.34%
7.64
+161.95%
2.92
Interest Expense Non Operating
6.19
0.00
0.00
—
Net Interest Income
23.67
-12.09%
26.92
+252.34%
7.64
+161.95%
2.92
Interest Expense
6.19
0.00
0.00
—
Interest Income Non Operating
29.86
+10.91%
26.92
+252.34%
7.64
+161.95%
2.92
Interest Income
29.86
+10.91%
26.92
+252.34%
7.64
+161.95%
2.92
Other Income Expense
-1.70
-273.79%
-0.45
+67.94%
-1.42
-2522.22%
-0.05
Other Non Operating Income Expenses
-1.70
-273.79%
-0.45
+67.94%
-1.42
-2522.22%
-0.05
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-446.21
-40.58%
-317.42
-34.54%
-235.94
-40.36%
-168.10
Net Income From Continuing Operation Net Minority Interest
-446.21
-40.58%
-317.42
-34.54%
-235.94
-40.36%
-168.10
Net Income From Continuing And Discontinued Operation
-446.21
-40.58%
-317.42
-34.54%
-235.94
-40.36%
-168.10
Net Income Continuous Operations
-446.21
-40.58%
-317.42
-34.54%
-235.94
-40.36%
-168.10
Normalized Income
-446.21
-40.58%
-317.42
-34.54%
-235.94
-40.36%
-168.10
Net Income Common Stockholders
-446.21
-40.58%
-317.42
-34.54%
-235.94
-40.36%
-168.10
Diluted EPS
—
-3.37
+14.68%
-3.95
-22.29%
-3.23
Basic EPS
—
-3.37
+14.68%
-3.95
-22.29%
-3.23
Basic Average Shares
—
94.14
+57.74%
59.68
+14.83%
51.98
Diluted Average Shares
—
94.14
+57.74%
59.68
+14.83%
51.98
Diluted NI Availto Com Stockholders
-446.21
-40.58%
-317.42
-34.54%
-235.94
-40.36%
-168.10
Line Item Trend 2021-12-31
Total Assets
—
Current Assets
—
Cash Cash Equivalents And Short Term Investments
—
Cash And Cash Equivalents
—
Cash Equivalents
—
Cash Financial
—
Other Short Term Investments
—
Prepaid Assets
5.82
Other Current Assets
—
Total Non Current Assets
—
Net PPE
—
Gross PPE
—
Accumulated Depreciation
—
Properties
0.00
Machinery Furniture Equipment
—
Construction In Progress
—
Other Properties
—
Leases
0.00
Other Non Current Assets
—
Total Liabilities Net Minority Interest
—
Current Liabilities
—
Payables And Accrued Expenses
—
Payables
—
Accounts Payable
—
Current Accrued Expenses
—
Current Debt And Capital Lease Obligation
—
Current Capital Lease Obligation
—
Total Non Current Liabilities Net Minority Interest
—
Long Term Debt And Capital Lease Obligation
—
Long Term Debt
—
Long Term Capital Lease Obligation
—
Stockholders Equity
—
Common Stock Equity
—
Capital Stock
—
Common Stock
—
Preferred Stock
—
Share Issued
—
Ordinary Shares Number
—
Treasury Shares Number
0.04
Additional Paid In Capital
—
Retained Earnings
—
Gains Losses Not Affecting Retained Earnings
—
Other Equity Adjustments
-0.27
Total Equity Gross Minority Interest
—
Total Capitalization
—
Working Capital
—
Invested Capital
—
Total Debt
—
Capital Lease Obligations
—
Net Tangible Assets
—
Tangible Book Value
—
Interest Payable
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-403.21
-37.91%
-292.37
-55.38%
-188.16
-22.46%
-153.65
Cash Flow From Continuing Operating Activities
-403.21
-37.91%
-292.37
-55.38%
-188.16
-22.46%
-153.65
Net Income From Continuing Operations
-446.21
-40.58%
-317.42
-34.54%
-235.94
-40.36%
-168.10
Depreciation Amortization Depletion
2.05
+22.47%
1.67
+0.00%
1.67
-0.59%
1.68
Depreciation And Amortization
2.05
+22.47%
1.67
+0.00%
1.67
-0.59%
1.68
Other Non Cash Items
0.28
-50.70%
0.57
-27.66%
0.79
-52.59%
1.66
Stock Based Compensation
45.85
-0.03%
45.86
+129.64%
19.97
+31.59%
15.18
Operating Gains Losses
0.07
+75.68%
0.04
-73.76%
0.14
+314.71%
0.03
Gain Loss On Investment Securities
-0.03
+14.29%
-0.04
-252.17%
0.02
-32.35%
0.03
Gain Loss On Sale Of PPE
0.10
+31.94%
0.07
-38.98%
0.12
0.00
Change In Working Capital
-3.40
+82.54%
-19.49
-174.09%
26.31
+589.07%
-5.38
Change In Prepaid Assets
0.99
+109.36%
-10.54
-415.73%
3.34
+180.53%
-4.14
Change In Payables And Accrued Expense
8.25
+192.14%
-8.96
-138.99%
22.97
+1959.92%
-1.24
Change In Payable
8.25
+192.14%
-8.96
-138.99%
22.97
+1959.92%
-1.24
Change In Account Payable
8.25
+192.14%
-8.96
-138.99%
22.97
+1959.92%
-1.24
Change In Other Current Assets
-12.64
0.00
0.00
0.00
Investing Cash Flow
-28.75
+85.91%
-204.08
-344.96%
83.31
-4.46%
87.20
Cash Flow From Continuing Investing Activities
-28.75
+85.91%
-204.08
-344.96%
83.31
-4.46%
87.20
Net PPE Purchase And Sale
-20.71
-771.63%
-2.38
-225.93%
-0.73
+76.23%
-3.07
Purchase Of PPE
-20.71
-771.63%
-2.38
-225.93%
-0.73
+76.23%
-3.07
Capital Expenditure
-20.71
-771.63%
-2.38
-225.93%
-0.73
+76.23%
-3.07
Net Investment Purchase And Sale
-8.04
+96.01%
-201.70
-340.00%
84.04
-6.90%
90.27
Purchase Of Investment
-180.53
+43.13%
-317.44
-617.19%
-44.26
+63.47%
-121.18
Sale Of Investment
172.49
+49.03%
115.74
-9.79%
128.30
-39.32%
211.44
Financing Cash Flow
890.31
+9.93%
809.89
+1390.92%
54.32
+45.28%
37.39
Cash Flow From Continuing Financing Activities
890.31
+9.93%
809.89
+1390.92%
54.32
+45.28%
37.39
Net Issuance Payments Of Debt
148.26
0.00
0.00
—
Issuance Of Debt
148.26
0.00
0.00
—
Repayment Of Debt
—
—
—
—
Long Term Debt Issuance
148.26
0.00
0.00
—
Long Term Debt Payments
—
—
—
—
Net Long Term Debt Issuance
148.26
0.00
0.00
—
Net Common Stock Issuance
734.61
-4.97%
773.05
+1376.16%
52.37
+42.07%
36.86
Proceeds From Stock Option Exercised
8.00
-78.29%
36.84
+1786.53%
1.95
+269.19%
0.53
Net Other Financing Charges
-0.56
—
—
—
Changes In Cash
458.35
+46.23%
313.45
+720.39%
-50.52
-73.91%
-29.05
Beginning Cash Position
437.39
+252.90%
123.94
-28.96%
174.47
-14.28%
203.52
End Cash Position
895.74
+104.79%
437.39
+252.90%
123.94
-28.96%
174.47
Free Cash Flow
-423.92
-43.83%
-294.75
-56.04%
-188.89
-20.53%
-156.71
Interest Paid Supplemental Data
4.34
0.00
0.00
—
Amortization Of Securities
-1.83
+49.08%
-3.60
-227.04%
-1.10
-186.36%
1.28
Common Stock Issuance
734.61
-4.97%
773.05
+1376.16%
52.37
+42.07%
36.86
Issuance Of Capital Stock
734.61
-4.97%
773.05
+1376.16%
52.37
+42.07%
36.86
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category